

FORM 9

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES (or securities convertible or exchangeable into listed securities¹)

Please complete the following:

Name of Listed Issuer: Kaneh Bosm Biotechnology Corp. (the "Issuer").

Trading Symbol: KBB

Date: July 4, 2018

Is this an updating or amending Notice: ☐ Yes ☒ No

If yes provide date(s) of prior Notices: _____.

Issued and Outstanding Securities of Issuer Prior to Issuance: 144,849,108

Date of News Release Announcing Private Placement: June 29, 2018

Closing Market Price on Day Preceding the Issuance of the News Release: \$0.48.

1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form) – N/A

Full Name & Residential Address of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) ⁽³⁾	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)

(1) Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals: Funds received from all placees and will be released to the Issuer on closing of the private placement.

(2) Indicate if Related Person.

(3) Securities issued are units, each unit consisting of a common share and a share purchase warrant.

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: _____

2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material.

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer:

4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities.

5. Description of securities to be issued:
 - (a) Class: _____
 - (b) Number: _____
 - (c) Price per security: _____
 - (d) Voting rights: _____

6. Provide the following information if Warrants, (options) or other convertible securities are to be issued:
 - (a) Number: _____
 - (b) Number of securities eligible to be purchased on exercise of Warrants (or options) _____
 - (c) Exercise price _____
 - (d) Expiry date _____

7. Provide the following information if debt securities are to be issued:
 - (a) Aggregate principal amount: _____

**FORM 9 – NOTICE OF PROPOSED ISSUANCE OF
LISTED SECURITIES**

January 2015
Page 2

- (b) Maturity date: _____
- (c) Interest rate: _____
- (d) Conversion terms: _____
- (e) Default provisions: _____
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address). If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer)
- _____
- (b) Cash: _____
- (c) Securities: _____
- (d) Other: _____
- (e) Expiry date of any options, warrants etc.: _____
- (f) Exercise price of any options, warrants etc.: _____
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship
- _____
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).
- _____
11. State whether the private placement will result in a change of control.
- _____
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders.
- _____

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102.

2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

The Issuer entered into a definitive purchase and sale agreement (the “Purchase Agreement”) with EU Cannabis Corp, (“EU Cannabis” or the “Vendor”) a private British Columbia corporation, to acquire all of the issued share capital of EU Cannabis (the “Acquisition”). EU Cannabis holds an option to acquire a 90% interest in three separate Greece industrial hemp licenses (the “Licenses”) from Cannatec Greece AE (“Cannatec”). Cannatec currently holds three Licenses covering a total of 16 acres situated within the Greek prefecture of Imathia. These Licenses were granted to Cannatec by the Hellenic Republic Ministry of Agricultural Development and Food and permit EU Cannabis to cultivate, manufacture, distribute and export industrial hemp and its many cannabidiol derived extracts.

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material:

The Issuer entered into the Purchase Agreement on June 29, 2018 with the Vendor, whereas the Issuer has agreed to purchase from the Vendor, one hundred percent of the issued and outstanding common shares of the Vendor in exchange for a cash payment of \$250,000 USD to the Vendor and the issuance of 18,000,000 common shares to the shareholders of the Vendor.

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:

- (a) Total aggregate consideration in Canadian dollars: \$8,969,200
- (b) Cash: 250,000 USD (\$329,200 CAD based on Bank of Canada exchange rate of \$1.3168 on June 29, 2018).
- (c) Securities (including options, warrants etc.) and dollar value:

**18,000,000 common shares issued at a deemed price of \$0.48
per common share**

- (d) Other: _____ .
- (e) Expiry date of options, warrants, etc. if any: _____ .
- (f) Exercise price of options, warrants, etc. if any: _____ .
- (g) Work commitments: _____ .
4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).

Arm's length negotiation.

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer:

None

6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾
Pamela Stone	2,000,000 Common shares	\$0.48 per Common share	N/A	NI 45-106 Section 2.12	Nil	Arm's Length
1061437 B.C. LTD.	1,750,000 Common shares	\$0.48 per Common share	N/A	NI 45-106 Section 2.12	Nil	Arm's Length
Iana Ivanova	750,000 Common shares	\$0.48 per Common share	N/A	NI 45-106 Section 2.12	Nil	Arm's Length
Milena Bulic	750,000 Common shares	\$0.48 per Common share	N/A	NI 45-106 Section 2.12	Nil	Arm's Length
Michael Blady	1,750,000 Common shares	\$0.48 per Common share	N/A	NI 45-106 Section 2.12	Nil	Arm's Length
1132902 B.C. LTD.	1,000,000 Common shares	\$0.48 per Common share	N/A	NI 45-106 Section 2.12	Nil	Arm's Length
Anthony Wilshere	10,000,000 Common shares	\$0.48 per Common share	N/A	NI 45-106 Section 2.12	Nil	Arm's Length
Total	18,000,000 Common shares					

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired:

Customary representation and warranties of title under Purchase Agreement and management due diligence.

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control

over 20% or more of the voting shares if known to the Issuer):
**1166450 B.C. Ltd., Suite 810 – 789 West Pender Street,
Vancouver, B.C. V6C 1H2**

- (b) Cash _____ .
- (c) Securities **1,440,000 Common shares** _____ .
- (d) Other _____ .
- (e) Expiry date of any options, warrants etc. _____
- (f) Exercise price of any options, warrants etc. _____ .

- 9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. **The finder is arm's length to the Issuer.**
- 10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. **N/A**

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated July 4, 2018.

Eugene Beukman
Name of Director or Senior
Officer

Signed: "Eugene Beukman"
Signature

Director
Official Capacity